Dhipatimendi rePasi Pose

Musi wa3 Zvita, 2024, mushonga mutsva weZepzelca (lurbinectin yekubaiwa jekiseni) wakatenderwa kutengeswa neNational Medical Products Administration (NMPA) yeChina kuburikidza nechirongwa chekuongorora zvinhu zvakakosha. Mushonga uyu unoratidzwa kurapa varwere vakuru vane chirwere chemapapu chemetastatic small cell caries...Verenga zvakawanda»

Musi wa31 Zvita, National Medical Products Administration (NMPA) yeChina yakabvumidza mushonga weVYLOYTM (zolbetuximab), pamwe chete ne fluoropyrimidine ne platinum-containing chemotherapy, wekurapa varwere vane chirwere cheganda chevanhu chisina kubviswa kana kuti chinopararira munzvimbo iyi...Verenga zvakawanda»

Zvita 31, 2024, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kambani") yakagamuchira mvumo yekushambadzira muChina kubva kuNational Medical Products Administration (NMPA) ye programmed cell death ligand1(PD-L1)-directed humanized monoclonal antibody ("mAb") tagitanlim...Verenga zvakawanda»

C-CAR031 mushonga wekudzivirira muviri weGPC3-targeting chimeric antigen receptor T-Cell (CAR-T), uri kudzidzwa kuti ushandiswe pakurapa HCC. Wakavakirwa paGPC3-targeting CAR-T itsva yakagadzirwa neAstraZeneca ichishandisa dominant negative transforming growth factor-beta receptor II dominant negati...Verenga zvakawanda»

Zvita 20, 2024, Hurumende yeNational Medical Products Administration (NMPA) yeChina yakabvumidza New Drug Application (NDA) yeDOVBLERON ® (taletrectinib adipate capsule), mushonga unodzivirira chirwere cheROS1 tyrosine kinase (TKI) wechizvarwa chinotevera, wekurapa varwere vakuru vane ROS yepamusoro kana kuti yakapararira munharaunda...Verenga zvakawanda»

C-CAR031 mushonga wekudzivirira chirwere cheT-Cell (CAR-T) unonzi autologous, wakashongedzerwa neGPC3-targeting chimeric antigen receptor (CAR-T), uri kudzidzwa kuti ushandiswe pakurapa HCC. Kufambira mberi kwekutsvaga C-CAR031 mu hepatocellular carcinoma (HCC) kwakaratidzwa nemuromo pamusangano wegore negore weAmerican Society of Clinical Oncology (ASCO) ...Verenga zvakawanda»

GT101 imushonga wemasero emunhu wakagadzirwa neTIL yakawedzerwa uye yakavandudzwa kubva mubundu remurwere. Kurapa uku kunoitwa nekuunganidza matishu ebundu kubva kuvarwere uye kubvisa TIL. TIL yakabviswa ichawedzerwa uchishandisa puratifomu yekugadzira yaGrit Bio inonzi StemTe...Verenga zvakawanda»

Masero eTAEST16001 masero eT akagadziriswa majini anoratidza hukama hwakakura pakati peNY-ESO-1-specific T-cell receptor (TCR) inotarisa NY-ESO-1 (inoratidzwa mumabundu akasiyana-siyana) positive soft tissue sarcoma (STS) muchikamu cheHLA-A*02:01. Chidzidzo chechikamu chekutanga chevarwere vane S yepamusoro...Verenga zvakawanda»

Zvita 04, 2024, New Drug Application (NDA) yemusanganiswa weTYVYT® (sintilimab injection) neELUNATE® (fruquintinib) yakapihwa mvumo muChina yekurapa varwere vane kenza ye endometrial yepamusoro vane Mismatch Repair proficient (pMMR) bundu dzine ...Verenga zvakawanda»

GC203 mushonga mutsva weTIL usina utachiona wakagadzirwa uchishandisa Juncell Therapeutics' proprietary DeepTIL® cell expansion platform uye NovaGMP® gene modification platform. DeepTIL® inoita kuti maTIL ave nesimba zvekuti hapana musanganiswa weIL-2 unodiwa mushure mekuiswa, uye...Verenga zvakawanda»

Glioblastoma Multiforme (GBM) ndeimwe yekenza inouraya zvakanyanya, uye varwere vakawanda vanodzoka vachirwara neGBM zvichienderana nekurapwa kwazvino uno kweGBM. GBM inodzoka (rGBM) inoratidza kurarama kwepakati pemwedzi isingasviki misere nesarudzo shoma dzekurapa. TX103 iCAR-T ce...Verenga zvakawanda»

RD13-02 chigadzirwa chemasero eCAR-T chinoshandiswa nevanhu vose chinotarisa CD7 chinobva kune vanopa vane hutano, uye chakagadzirirwa kurapa T-cell inodzokera shure kana kuti isingashande zvakanaka nemasero eT-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL). Yakagadziriswa majini kudzivirira fratricide, graft-versus-host disease (GvHD), uye host-versus-...Verenga zvakawanda»